ABSTRACT. We performed continuous renal replacement therapy (CRRT) in clinically healthy dogs (n=7) to evaluate the utility of nafamostat mesilate (NM) as an anticoagulant. In 3 of the 7 dogs, CRRT had to be discontinued before the target duration due to coagulation in the extracorporeal circuit, into which NM was administered constantly at the rate of 2.0-6.0 mg/kg per hour. The rate of administration of NM was greater than the recommended dose of NM in humans. Further, all the dogs suffered vomiting during CRRT with NM infusion. We therefore recommend that NM is not used as an anticoagulant during CRRT in dogs.
, Chihiro YOSHIOKA 1) , Koji MINAMI 1) , Takumi OKAWA 1) , Hiroko HIRAOKA 1) , Kazuhito ITAMOTO 2) , Takuya MIZUNO 1) and Masaru OKUDA ABSTRACT. We performed continuous renal replacement therapy (CRRT) in clinically healthy dogs (n=7) to evaluate the utility of nafamostat mesilate (NM) as an anticoagulant. In 3 of the 7 dogs, CRRT had to be discontinued before the target duration due to coagulation in the extracorporeal circuit, into which NM was administered constantly at the rate of 2.0-6.0 mg/kg per hour. The rate of administration of NM was greater than the recommended dose of NM in humans. Further, all the dogs suffered vomiting during CRRT with NM infusion. We therefore recommend that NM is not used as an anticoagulant during CRRT in dogs. Continuous renal replacement therapy (CRRT) is a blood purification method that uses a hemofilter/hemodialyzer and an extracorporeal circuit (ECC). In human medicine, it has been widely used to treat acute renal failure (ARF) in critically ill patients [15, 16] . In contrast, in veterinary medicine, CRRT is an emerging modality that has been investigated recently but is utilized in only a few veterinary facilities [2, 4, 6] . Therefore, information regarding CRRT in veterinary medicine is fairly limited.
CRRT typically requires the administration of anticoagulants to prevent circuit clotting. Although heparin is the most common choice among anticoagulants, it is considered to be associated with bleeding complications, especially in high-risk patients [10, 15] . Nafamostat mesilate (NM) is a synthetic serine protease inhibitor that exerts an anticoagulation effect by blocking activated factors VII (VIIa), Xa, XIIa, and thrombin [11] . It has been used as an alternative anticoagulant in humans in Japan [8, 10] . The use of NM is associated with a lower bleeding risk than is heparin, because NM has a short half-life and allows minimal systemic anticoagulation [10] . However, there are no reports regarding the use of NM as an anticoagulant during CRRT in veterinary medicine. Therefore, in this study, we evaluated the suitability of NM as an anticoagulant during CRRT in clinically healthy dogs.
Six adult beagles (males, 2; females, 4) and 1 adult mongrel dog (female) weighing 7.9-16.0 kg (mean  SD, 11.3  2.7 kg) were used in this study. The dogs were maintained for experimental purposes, housed individually in cages, fed commercial dry food, and given free access to water. The study was conducted in accordance with the guidelines outlined by the Experimental Animal Committee of Yamaguchi University, Japan. They were evaluated by testing for complete blood count (CBC), serum blood chemistry, radiography, and ultrasonography before each experiment and pronounced to be clinically healthy. Each dog was anesthetized with medetomidine (0.02 mg/kg, intramuscular (IM)) and midazolam (0.3 mg/kg, IM) during the placement of the catheter. Following the application of 1% lidocaine over the proposed site of catheter placement, a 12-Fr dual-lumen catheter (GentleCath; Nippon Sherwood, Tokyo, Japan) was inserted into the right external jugular vein. The distal tip of the catheter was advanced to the level of the right atrium. Thoracic radiography was used to confirm the correct placement of the catheter tip. Anesthesia was reversed with atipamezole (0.1 mg/kg, IM) after catheterization was completed. The dogs were then carefully monitored until they were completely awake. Continuous venovenous hemodiafiltration, which uses a convective and diffusive solute clearance with ultrafiltration, was initiated as the mode of CRRT. An automated renal replacement therapy system (ACH-07S; Asahi Medical, Tokyo, Japan) and an infusion pump (TOP-2200; TOP, Tokyo, Japan) were used for CRRT. The system utilized an ECC (CHD-770N; Asahi Medical) with an integrated 0.3-m 2 hemofilter (PANFLO APF-03S; Asahi Medical). The priming volume of the ECC including the hemofilter was 113.5 ml and the ECC was primed with 0.9 % sodium chloride. Commercially available balanced electrolyte solution (Sublood BS; Fuso Pharmaceutical Industries, Osaka, Japan) was used as a dialysate and replacement fluid. The solution contained 140.0 mEq/l sodium, 2.0 mEq/l potassium, 111.5 mEq/l chloride, 7.0 mg/ dl calcium, 1.0 mEq/l magnesium, 0.5 mEq/l acetate, 35 mEq/l bicarbonate, and 100.0 mg/dl glucose and had been warmed to 38C in the thermoregulator until it was used. The body of the dog, the ECC, dialysate, and replacement fluid were constantly warmed throughout CRRT by using hand warmers, an electrical heating mat, and a halogen heater.
CRRT was performed on conscious dogs by using the post-dilution method (Fig. 1) . The initial extracorporeal flow rate was based on a human pediatric CRRT protocol [14] and comprised a maximum blood flow rate (Q b ) of 2 ml/kg per minute (range, 16 to 32 ml/min), dialysate flow rate (Q d ) of 200 ml/hr, and ultrafiltration rate (Q f ) of 8% of Q b . The ultrafiltrate was replaced by the same amount of replacement fluid. The initial Q b was adjusted to half of the maximum Q b and was increased gradually to the maximum rate in the first 10 min. After the Q b reached the maximum rate, the pumps for ultrafiltration, dialysis, and replacement fluid administrations were turned on. The Q b , Q f , and Q d were maintained at the same rates until the termination of CRRT. When CRRT was completed for the arranged duration time or needed to be discontinued due to ECC coagulation, the blood in the ECC was returned to the body of the dogs at the rate of half of the Q b or within 15-20 min.
The target duration for CRRT was set at 16 hr. CRRT was initiated approximately 1.5-2.0 hr after the dogs completely recovered from anesthesia. NM was used as an anticoagulant for all the dogs. According to the anecdotal evidence for the pediatric dose of NM in humans and a preliminary study (data not shown), the initiation rate of NM was established as 2.0 mg/kg/hr. After the initiation of CRRT, the activated clotting time (ACT) was monitored every 1 hr. Visual ACT measurement was carried out according to the procedure described by Gerber et al. [5] . The infusion rate of NM was maintained to keep ACT values between 100 and 150 sec. Blood parameters-including CBC, blood urea nitrogen (BUN), creatinine, sodium, potassium, chloride, total calcium, phosphate, albumin, total protein, and C-reactive protein-were measured before and after CRRT and 1 week after finishing the experiment. Venous blood gas analysis was also performed before and after CRRT.
Statistical analyses were performed using the statistical software Prism 5 (GraphPad Software, San Diego, CA, U.S.A.). All data was expressed as mean  standard deviation. Intergroup comparisons for blood chemistry and venous blood gas analysis were analyzed using one-way analysis of variance for repeated measures with Bonferroni post test. Paired data were analyzed by Student's t-test. A p value <0.05 was considered statistically significant.
In 3 of the 7 dogs, CRRT had to be discontinued before the target duration due to ECC coagulation, although the target duration was set as 16 hr. The duration of CRRT was thus 11-16 hr (mean  SD, 14.4  2.1 hr). The post-procedure platelet counts were significantly lower than the preprocedure values within the group with ECC coagulation ( Table 1 ). The post-procedure PCV values were slightly decreased in comparison to pre-procedure values, albeit without a difference between the groups with/without ECC coagulation. Our results suggested that ECC coagulation had a greater effect on the platelet counts than on PCV. In this experiment, we noted the occurrence of ECC clotting at an early stage and began to return the blood in the ECC to the dogs promptly. Therefore, it was possible to return most of the blood components in the ECC to the patients. However, the anticoagulation by NM was not adequate for performing CRRT through the target duration. ACT was monitored every 1 hr to determine the dose of NM. Nevertheless, ECC coagulation was observed in 3 of the 7 dogs. Although infusion of NM did not affect PT, fibrinogen, or ATIII, it prolonged ACT and APTT, between which there was a strong correlation (correlation coefficient = 0.83) (data not shown). More frequent monitoring of ACT may have been necessary to avoid ECC coagulation; however, measurement of APTT may not have an advantage over ACT for coagulation monitoring since APTT measurement is time-consuming and is not cost-effective compared to ACT measurement.
Changes in blood chemistry and venous blood gas parameters before and after CRRT are summarized in Table 2 . There were no significant differences observed in the parameters between the groups with/without ECC coagulation (data not shown). Although the total calcium level decreased significantly after CRRT, the values remained within the reference range. On the other hand, potassium levels decreased significantly, and hypokalemia (range, 2.8-3.2 mg/dl) was observed in 4 of the 7 dogs. The potassium concentration of the dialysate (2.0 mEq/l) is intended for use in patients with renal failure who are supposed to have higher blood potassium concentrations than are normal patients. Therefore, when the patients have normal or lower potassium concentrations, monitoring and adjustment of potassium levels is important. The dogs presented significantly lower BUN values after CRRT (mean  SD, 16.0  4.1 mg/dl) compared to the values before CRRT (mean  SD, 6.3  2.8 mg/dl). Values for all the parameters were restored to within the normal range 1 week after CRRT.
A minimum rate of 2.0-6.0 mg/kg/hr was required in this study (Table 3) , while the recommended dose of NM for CRRT is 0.1-0.5 mg/kg/hr in adult humans and 0.1-1.0 mg/ kg/hr in pediatric patients [13, 14] . Pediatric patients require a greater extracorporeal circulation volume per kg of body weight as well as a lower blood flow rate than adults due to their small body mass; this requirement contributes to the increased dose of anticoagulant needed [14] . The dogs included in this study had low body mass similar to pediatric patients, and this may have caused the increased dose of NM needed. Furthermore, the difference in drug clearance rates from the blood might contribute to the difference in the anticoagulant dose. In humans, the half-life of NM in blood has been reported to be approximately 23 min after continuous intravenous infusion [1] , while in dogs it is reported to be 16 min [3] . NM is inactivated by hydrolysis catalyzed by esterases in the blood and liver [17] , and the esterase activity in the blood of dogs is reported to be higher than that in humans [7] . Because the half-life of NM during CRRT was reported to be 5-8 min in humans, i.e., shorter [10] , the halflife of NM during CRRT might be correspondingly shorter in dogs.
All the dogs presented with vomiting 2-11 times each during CRRT (Table 3) and NM was suspected to cause vomiting. To clarify this, two of the dogs were infused NM at the rate of 2.0-4.0 mg/kg/hr for 4 hr in the experimental setting without performing CRRT (Table 3) . During the infusion, these dogs presented with vomiting 2 and 4 times, respectively. However, neither of the dogs presented vomiting after ceasing the NM infusion. One may concern that NM concentration might decrease during CRRT since NM was administered into the ECC; therefore, NM infusion in the non-CRRT setting may not be equivalent to the infusion during CRRT. However, we have performed CRRT on 8 dogs using heparin as an anticoagulant, no dogs presented vomiting during CRRT (data not shown). It is also suggested that the side effect of vomiting observed in this study was associated with the NM infusion. Vomiting associated with NM has been previously reported in dogs [9] . According to the subacute toxicity study, NM caused salivation and vomiting following intravenous administration in dogs at a dose of 3.5 mg/kg, and the maximum non-effective dose was estimated to be 0.5 mg/kg. In this previous report, NM was administered at a constant rate via an infusion for 1 hr, and repeated daily for 30 d, although the doses between 0.5 mg/kg and 3.5 mg/kg were not evaluated. The mechanism underlying the causation of vomiting by NM in dogs remains to be identified. However, we suspect that NM or its metabolites stimulate the chemoreceptor trigger zone in the area postrema and cause vomiting, because we administered NM intravenously and subsequently observed acute onset of vomiting. CRRT has been utilized for patients with severe conditions such as acute pancreatitis, sepsis, and multiple organ failure [8, 12, 15] . Therefore, it is essential to avoid vomiting associated with NM because it can cause aspiration pneumonia and other deleterious effects.
In summary, although NM is widely used in humans due to its lowered bleeding risks, it was required in higher doses during CRRT in dogs and may cause frequent vomiting. On the basis of these findings, we do not recommend NM as an anticoagulant during CRRT in dogs. 
